Day Two Highlighted Sir Richard Branson’s Journey through Forty Years
of Business, the Connections between Biotech and National Security, and
an Overview of How the
Upcoming Convention Highlights Include:
Media Coverage: The event is open to the press. All members of the media who attend the event must check in – and be provided credentials at Media Registration. Names and IDs will be checked. Seating for print media is NOT GUARANTEED. Once designated seating is full, media will be directed to an overflow room.
Media entrance: Media may enter at the D/E entrances
Live Truck Pre-Set:
Still Photography Pre-Set:
IMPORTANT NOTE: Those bringing still cameras will be escorted to set location. All photographs will be captured within the first five minutes of the Keynote.
Ernst & Young’s 2014 biotechnology industry report explores approaches that allow companies to “unlock value” by conducting R&D in ways that are both more capital-efficient and better aligned with the need to demonstrate value. The report highlights three such approaches: precision medicine, adaptive trials and pre-commercial collaborations.
The Accelerating Medicines Partnerships (AMP) is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies focused on transforming the current model for developing new treatments. The Session will highlight the goals and implementation plans for the new AMP program as well as explore the evolution of large-scale public private partnerships in an evolving innovation ecosystem.
The science driving personalized medicine continues to push innovation in medicine towards better patient (diagnosis, treatments, and cures). However, the regulatory, reimbursement, healthcare practice and research environments are not currently conducive to experiencing the full potential of personalized medicine. This panel will explore these challenges, and suggest policy solutions that are critical to the success of personalized medicine.
This session will discuss provisions in the 2012 FDA Safety and Innovation Act intended to facilitate patient involvement in drug development. These include an initiative to incorporate patient perspectives on disease severity and medical need into the review process; a FDASIA section to foster participation of patient representatives in appropriate
Disease foundations are playing an increasingly important role in advancing research and helping to bring new treatments to market. Their unique expertise in specific disease areas can be invaluable to developing and disseminating new research tools, technologies and clinical protocols. In addition, these organizations have a keen understanding of patient needs, and access to clinical thought leaders and patients, which can enhance and accelerate the clinical development of new treatments. Industry and foundation executives share what they view as the key opportunities and challenges for industry-foundation collaborations.
If realized, disease-modifying interventions targeted toward Alzheimer’s disease – treatments which actually slow or halt disease progression – would be a tremendous breakthrough for patients, family members and researchers. Research into disease-modifying interventions is increasingly targeted toward earlier stage patients. Although early intervention may offer the most promise for patients, this earlier focus creates challenges for researchers who have traditionally been asked to provide co-primary outcome measures which demonstrate both the cognitive as well as functional impacts of therapy. In order to identify the appropriate clinical trial endpoints – those which demonstrate clinical meaningfulness of treatment effects in the earlier stages of disease – a robust dialogue between researchers, regulators, patients, and caregivers must take place. In this session, a panel of notable researchers, informed advocates, and regulatory experts will present an overview of the current paradigm, discuss the anticipated challenges as research focuses earlier, and debate future requirements.
This session will look forward at the possible growth opportunities in the global vaccines market. The last ten years saw the launch of several multi-billion dollar vaccines such as the conjugated pneumonia and HPV vaccines. Were these vaccines just rare events in the market or are there other products that represent growth in global vaccines? Are new pediatric vaccines the only true blockbusters or does the future point to specialized vaccines against nosocomial infections, chronic diseases and cancer? Panelists will discuss the prospects for both global and niche vaccines and whether the projected growth of the vaccine market is possible.
The term “value” is swiftly pushing the U.S. marketplace through system-wide changes, particularly since the passage of health reform. Most health care stakeholders are growing increasingly concerned that value is a euphemism for cost, rather than a healthy balance of cost, quality and patient outcomes, and fear it may eventually discourage future innovations. Launching new products in an environment where unit cost reigns over total cost of care and outcomes will be challenging. In other parts of the world, assessing a product’s value is well-established and is part of the decision-making process. Learn how biopharmaceuticals, payers and providers will incorporate the drive for value in their U.S. organizations moving forward.
Day Two Session Highlights Included:
In a special Keynote Luncheon, Sir
This year’s BIO/Battelle State Initiatives Report describes the size, scope and performance of the bioscience industry sector at the national, state and metro level and reports on trends in state bioscience industry development efforts. A panel of state Governors examined in detail a series of key performance metrics and discussed state policies and programs designed to accelerate the growth of the biosciences. The discussion panel provided an analysis on where the industry stands today and how states can continue fostering a bioscience economy in challenging economic times.
Follow the 2014 Convention @BIOConvention, and join the conversation @IAmBIOtech.
Media registration is open from
The Convention also features the
Upcoming BIO Events
Livestock Biotech Summit
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across
For more information:
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech